bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.02.12.705593

Multiscale Analysis of PNPLA2 and PNPLA3 Membrane Targeting

Abstract

Lipid droplets (LDs) are dynamic organelles that regulate cellular lipid storage and mobilization through the coordinated action of LD-associated proteins. Patatin-like phospholipase domain-containing proteins PNPLA2 (ATGL) and PNPLA3 are central regulators of lipid metabolism, yet the molecular mechanisms underlying their membrane targeting and distinct enzymatic activities remain poorly understood. Here, we combine coarse-grained and all-atom molecular dynamics simulations with enhanced sampling to investigate how PNPLA2 and PNPLA3 associate with endoplasmic reticulum (ER) and LD membranes. Despite sharing a conserved N-terminal patatin domain, the two proteins exhibit distinct membrane-binding modes driven by divergent C-terminal amphipathic helices. In both proteins, membrane association is mediated primarily by deep insertion of C-terminal helices, while the patatin domain provides surface contact. PNPLA2 forms a deeply embedded U-shaped helical bundle on LDs that induce pronounced membrane curvature and promote opening of the catalytic dyad, consistent with its high triglyceride lipase activity. In contrast, PNPLA3 engages membranes through a more flexible helical arrangement that maintains a compact catalytic geometry and limits substrate accessibility. Membrane composition further modulates these interactions and leads to protein-specific lipid redistribution and curvature remodeling. Fluorescence microscopy experiments validate the computational predictions and demonstrate that mutation of a single arginine residue within the C-terminal region is sufficient to reduce LD targeting of both proteins. These results establish a mechanistic connection between membrane binding, conformational plasticity, and catalytic regulation in PNPLA2 and PNPLA3. Our work provides molecular insights into how lipid environments tune the function of LD-associated enzymes. Author SummaryLDs are essential cellular organelles that control how fats are stored and released, a process that relies on the precise recruitment and regulation of lipid-metabolizing enzymes. Our work focuses on two closely related enzymes, PNPLA2 (ATGL) and PNPLA3, which play central but distinct roles in lipid metabolism and metabolic diseases. Using a combination of multiscale modeling simulations and fluorescence microscopy, we examine how these proteins recognize and bind to ER and LD membranes. Although PNPLA2 and PNPLA3 share a conserved catalytic core, we show that they interact with membranes in different ways due to differences in their C-terminal amphipathic helices. We find that PNPLA2 forms a deeply embedded helical arrangement that reshapes the membrane and promotes access to its catalytic site, which explains why it typically shows strong lipase activity. In contrast, PNPLA3 adopts a more compact membrane-bound catalytic geometry that limits substrate access and enzymatic activity. We further applied fluorescence microscopy to experimentally validate the computational predictions. The results show that mutation of a single arginine residue within the membrane-binding helix reduces LD targeting. These findings reveal how membrane association and protein conformational dynamics jointly regulate catalytic accessibility and activity.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kumar, A., Teskey, G., Mottillo, E., Huang, Y.-m. M.. 2026-02-14. Multiscale Analysis of PNPLA2 and PNPLA3 Membrane Targeting. https://doi.org/10.64898/2026.02.12.705593

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Design of colipids with controlled lateral distance of head group moieties for targeting strategies in the field of lipid-based nanoparticles

Lipid nanoparticles and liposomes are nanoparticle drug formulations which are firmly established in clinics. In order to expand their application and improve efficacy, surface modifications can be a key strategy, especially for cell specific targeting. Targeting can be achieved by integrating ligand functionalized lipids or lipidoids on the nanoparticle surface. In this case, not solely the targeting ligand itself, but also the structure of the whole targeting lipid/lipidoid can affect the interaction of the targeting ligand with the binding motive on cells. Especially, distal spacer structures between lipid anchor and ligand unit, often composed of polyethylene glycol chains, provide a certain distance of the ligand from the nanoparticle surface. A concept which is currently neglected is the control of the lateral distance between ligand structures on the nanoparticle. Herein we investigated the possibility to design lipidoids with a lateral spacer composed of polyethylene glycol units. We synthesized and characterized different lipidoids which provide a primary amine in the head group for possible ligand coupling. In our model lipidoids the head groups were functionalized with a paramagnetic probe to apply electron paramagnetic resonance (EPR) methods for the characterization of the lipidoid interaction with model nanoparticles, in our case liposomes. Continuous wave EPR was used to study the efficiency of the novel lipidoids to integrate into lipid bilayers of model liposomes, which was shown to depend on lipidoid structure and liposome composition. Furthermore, using double electron-electron resonance (DEER), we observed lipidoid conformational changes occurring upon integration into liposomes.

biophysics↗

Binding mechanisms of therapeutic antibodies to human claudin-18.2

Claudin-18.2 (CLDN18.2) is a tight junction component with highly restricted expression in the paracellular space of nonmalignant gastric epithelial cells. It becomes accessible on tumor cell surface during malignant transformation, making CLDN18.2 an attractive target for targeted therapies against gastric cancer. Recently, zolbetuximab has become the first FDA-approved monoclonal antibody that targets CLDN18.2 in advanced gastric cancer, and others like osemitamab have entered phase 3 clinical trials. However, the high-resolution structure of CLDN18.2 is lacking, and how CLDN18.2 is recognized by therapeutic antibodies remains undefined. Here, we report cryo-EM structures of human claudin-18.2 (hCLDN18.2) in complex with the Fab fragments of zolbetuximab and osemitamab, revealing the structure of hCLDN18.2 and its binding mechanism to the therapeutic antibodies. Further analyses reveal that three residues in the first extracellular loop of hCLDN18.2 that are different from human claudin-18.1 (hCLDN18.1) play a critical role in antibody binding. Our data elucidate the structural basis for selective binding of therapeutic antibodies to hCLDN18.2, which should aid rational design of next-generation immunotherapies targeting hCLDN18.2.

biophysics↗

Structural relationships between the SLC12 cotransporter C-terminal domain, universal stress proteins and adenylating enzymes

Several SLC12 cotransporters bind ATP in a cytoplasmic C-terminal domain (CTD). We analysed 16,192 CTD-containing SLC12 sequences and compared 42,845 representative structures to examine the relationship between this nucleotide site, universal stress proteins (USPs) and adenylating enzymes. In phosphorylated NKCC1, D891 and D927 lie near the ATP phosphate chain, while R801 and K889 form a basic phosphate-binding clamp. NKCC1 retains this arrangement, whereas KCC paralogs replace or lose several corresponding groups. In structural comparisons with USP and adenylating-enzyme references, both CTD lobes score between universal stress proteins and EC-annotated domains, and the two lobes form separate lineages that include bacterial transporters. Lobe-specific and nucleotide-frame comparisons place ATP in the corresponding structural region used for -phosphate chemistry by catalytic members of this fold. Published work on UspG provides a precedent for protein-bound AMP in a natural USP. In the examined SLC12 structures and USP models, candidate protein hydroxyls lack an in-line geometry for attack at ATP P. Protein adenylation would require a change in protein or nucleotide geometry, or a different acceptor. These results define a structural basis for testing conditional protein adenylation at SLC12 nucleotide sites. The required evidence is a covalent protein-AMP adduct, identification of its acceptor and measurement of the expected pyrophosphate coproduct, with soluble nucleotide analysis to distinguish accompanying ATP reactions.

biophysics↗